Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg (LEVEQ-3)

Bayer

Status and phase: Completed; Phase 1

Conditions: Contraceptives, Postcoital

Treatments: Drug: Levonorgestrel Emergency Pill (BAY86-5028); Drug: Postinor 2

Study type: Interventional

Funder types: Industry

Identifiers

NCT01073904

14782

Details and patient eligibility

About

A single dose, two treatments (Postinor-2 and Opxion), two periods, two sequences, crossover, randomized, prospective design was chosen with a washout of 14 days between the two study periods. Treatment groups are balanced with the same number of male healthy volunteers who were randomly assigned to the study drug administration sequences.

Enrollment: 32 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis.

Exclusion criteria

• History of illnesses or any organic abnormalities that could affect the results of the study.
• History of tobacco or alcohol abuse or regular use of recreational or therapeutic drugs.
• Subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 half-lives (whichever is longest) before study startup.

Trial design

32 participants in 2 patient groups

Arm 1

Experimental group

Treatment:

Drug: Levonorgestrel Emergency Pill (BAY86-5028)

Arm 2

Active Comparator group

Treatment:

Drug: Postinor 2